Cargando…
Adverse Prognostic Impact of the KIT D816V Transcriptional Activity in Advanced Systemic Mastocytosis
In systemic mastocytosis (SM), qualitative and serial quantitative assessment of the KIT D816V mutation is of diagnostic and prognostic relevance. We investigated peripheral blood and bone marrow samples of 161 patients (indolent SM (ISM), n = 40; advanced SM, AdvSM, n = 121) at referral and during...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961551/ https://www.ncbi.nlm.nih.gov/pubmed/33806359 http://dx.doi.org/10.3390/ijms22052562 |
_version_ | 1783665285545328640 |
---|---|
author | Naumann, Nicole Lübke, Johannes Baumann, Sofie Schwaab, Juliana Hoffmann, Oliver Kreil, Sebastian Dangelo, Vito Reiter, Lukas Bugert, Peter Kristensen, Thomas Sotlar, Karl Haselmann, Verena Schneider, Sven Metzgeroth, Georgia Weiss, Christel Popp, Henning D. Fabarius, Alice Hofmann, Wolf-Karsten Cross, Nicholas C. P. Reiter, Andreas Jawhar, Mohamad |
author_facet | Naumann, Nicole Lübke, Johannes Baumann, Sofie Schwaab, Juliana Hoffmann, Oliver Kreil, Sebastian Dangelo, Vito Reiter, Lukas Bugert, Peter Kristensen, Thomas Sotlar, Karl Haselmann, Verena Schneider, Sven Metzgeroth, Georgia Weiss, Christel Popp, Henning D. Fabarius, Alice Hofmann, Wolf-Karsten Cross, Nicholas C. P. Reiter, Andreas Jawhar, Mohamad |
author_sort | Naumann, Nicole |
collection | PubMed |
description | In systemic mastocytosis (SM), qualitative and serial quantitative assessment of the KIT D816V mutation is of diagnostic and prognostic relevance. We investigated peripheral blood and bone marrow samples of 161 patients (indolent SM (ISM), n = 40; advanced SM, AdvSM, n = 121) at referral and during follow-up for the KIT D816V variant allele frequency (VAF) at the DNA-level and the KIT D816V expressed allele burden (EAB) at the RNA-level. A round robin test with four participating laboratories revealed an excellent correlation (r > 0.99, R(2) > 0.98) between three different DNA-assays. VAF and EAB strongly correlated in ISM (r = 0.91, coefficient of determination, R(2) = 0.84) but only to a lesser extent in AdvSM (r = 0.71; R(2) = 0.5). However, as compared to an EAB/VAF ratio ≤2 (cohort A, 77/121 patients, 64%) receiver operating characteristic (ROC) analysis identified an EAB/VAF ratio of >2 (cohort B, 44/121 patients, 36%) as predictive for an advanced phenotype and a significantly inferior median survival (3.3 vs. 11.7 years; p = 0.005). In terms of overall survival, Cox-regression analysis was only significant for the EAB/VAF ratio >2 (p = 0.006) but not for VAF or EAB individually. This study demonstrates for the first time that the transcriptional activity of KIT D816V may play an important role in the pathophysiology of SM. |
format | Online Article Text |
id | pubmed-7961551 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79615512021-03-17 Adverse Prognostic Impact of the KIT D816V Transcriptional Activity in Advanced Systemic Mastocytosis Naumann, Nicole Lübke, Johannes Baumann, Sofie Schwaab, Juliana Hoffmann, Oliver Kreil, Sebastian Dangelo, Vito Reiter, Lukas Bugert, Peter Kristensen, Thomas Sotlar, Karl Haselmann, Verena Schneider, Sven Metzgeroth, Georgia Weiss, Christel Popp, Henning D. Fabarius, Alice Hofmann, Wolf-Karsten Cross, Nicholas C. P. Reiter, Andreas Jawhar, Mohamad Int J Mol Sci Article In systemic mastocytosis (SM), qualitative and serial quantitative assessment of the KIT D816V mutation is of diagnostic and prognostic relevance. We investigated peripheral blood and bone marrow samples of 161 patients (indolent SM (ISM), n = 40; advanced SM, AdvSM, n = 121) at referral and during follow-up for the KIT D816V variant allele frequency (VAF) at the DNA-level and the KIT D816V expressed allele burden (EAB) at the RNA-level. A round robin test with four participating laboratories revealed an excellent correlation (r > 0.99, R(2) > 0.98) between three different DNA-assays. VAF and EAB strongly correlated in ISM (r = 0.91, coefficient of determination, R(2) = 0.84) but only to a lesser extent in AdvSM (r = 0.71; R(2) = 0.5). However, as compared to an EAB/VAF ratio ≤2 (cohort A, 77/121 patients, 64%) receiver operating characteristic (ROC) analysis identified an EAB/VAF ratio of >2 (cohort B, 44/121 patients, 36%) as predictive for an advanced phenotype and a significantly inferior median survival (3.3 vs. 11.7 years; p = 0.005). In terms of overall survival, Cox-regression analysis was only significant for the EAB/VAF ratio >2 (p = 0.006) but not for VAF or EAB individually. This study demonstrates for the first time that the transcriptional activity of KIT D816V may play an important role in the pathophysiology of SM. MDPI 2021-03-04 /pmc/articles/PMC7961551/ /pubmed/33806359 http://dx.doi.org/10.3390/ijms22052562 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Naumann, Nicole Lübke, Johannes Baumann, Sofie Schwaab, Juliana Hoffmann, Oliver Kreil, Sebastian Dangelo, Vito Reiter, Lukas Bugert, Peter Kristensen, Thomas Sotlar, Karl Haselmann, Verena Schneider, Sven Metzgeroth, Georgia Weiss, Christel Popp, Henning D. Fabarius, Alice Hofmann, Wolf-Karsten Cross, Nicholas C. P. Reiter, Andreas Jawhar, Mohamad Adverse Prognostic Impact of the KIT D816V Transcriptional Activity in Advanced Systemic Mastocytosis |
title | Adverse Prognostic Impact of the KIT D816V Transcriptional Activity in Advanced Systemic Mastocytosis |
title_full | Adverse Prognostic Impact of the KIT D816V Transcriptional Activity in Advanced Systemic Mastocytosis |
title_fullStr | Adverse Prognostic Impact of the KIT D816V Transcriptional Activity in Advanced Systemic Mastocytosis |
title_full_unstemmed | Adverse Prognostic Impact of the KIT D816V Transcriptional Activity in Advanced Systemic Mastocytosis |
title_short | Adverse Prognostic Impact of the KIT D816V Transcriptional Activity in Advanced Systemic Mastocytosis |
title_sort | adverse prognostic impact of the kit d816v transcriptional activity in advanced systemic mastocytosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961551/ https://www.ncbi.nlm.nih.gov/pubmed/33806359 http://dx.doi.org/10.3390/ijms22052562 |
work_keys_str_mv | AT naumannnicole adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis AT lubkejohannes adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis AT baumannsofie adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis AT schwaabjuliana adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis AT hoffmannoliver adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis AT kreilsebastian adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis AT dangelovito adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis AT reiterlukas adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis AT bugertpeter adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis AT kristensenthomas adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis AT sotlarkarl adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis AT haselmannverena adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis AT schneidersven adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis AT metzgerothgeorgia adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis AT weisschristel adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis AT popphenningd adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis AT fabariusalice adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis AT hofmannwolfkarsten adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis AT crossnicholascp adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis AT reiterandreas adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis AT jawharmohamad adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis |